Intensive care unit versus high-dependency care unit admission on mortality in patients with septic shock: a retrospective cohort study using Japanese claims data.

Authors:
Endo K; Mizuno K; Seki T; Joo WJ; Takeda C and 2 more

Journal:
J Intensive Care

Publication Year: 2022

DOI:
10.1186/s40560-022-00627-2

PMCID:
PMC9306250

PMID:
35869538

Journal Information

Full Title: J Intensive Care

Abbreviation: J Intensive Care

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Critical Care Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"availability of data and materials no data are available. declarations ethics approval and consent to participate the study protocol was approved by the ethics committee of kyoto university graduate school and faculty of medicine (r2653"

Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe study protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (R2653). Consent for publicationNot applicable. Competing interestsKoji Kawakami has received research funds from Eisai Co., Ltd.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Pfizer Inc.; Stella Pharma Corporation; CMIC Co., Ltd.; Suntory Beverage & Food Ltd.; Mitsubishi Corporation, and Real World Data Co., Ltd.; consulting fees from LEBER Inc.; JMDC Inc.; Shin Nippon Biomedical Laboratories Ltd.; Kaken Pharmaceutical Co., Ltd.; and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems; Inc.; honorarium from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, and Pharma Business Academy; and holds stock in Real World Data Co., Ltd. Competing interests Koji Kawakami has received research funds from Eisai Co., Ltd.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Pfizer Inc.; Stella Pharma Corporation; CMIC Co., Ltd.; Suntory Beverage & Food Ltd.; Mitsubishi Corporation, and Real World Data Co., Ltd.; consulting fees from LEBER Inc.; JMDC Inc.; Shin Nippon Biomedical Laboratories Ltd.; Kaken Pharmaceutical Co., Ltd.; and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems; Inc.; honorarium from Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, and Pharma Business Academy; and holds stock in Real World Data Co., Ltd."

Evidence found in paper:

"Funding Not applicable."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025